Fig. 7: DECR1 KO affects lipid metabolism and decreases CRPC tumour growth.
From: 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer
a Representative pictures of LNCaP AI CTL (top image) or DECR1 KO (bottom image) tumour orthografts monitored by ultrasound imaging (left). Quantification of tumour volume using ultrasonography (right). b Representative pictures of hematoxylin/eosin staining on orthografts from LNCaP AI CTL (top) or DECR1 KO (bottom) cells. C = cancer cells, N = necrotic region. Quantification of the proportion of cancer cells (right). Scale bar represents 1000 µm. c Representative heatmaps on data from Raman spectroscopy using 532 nm excitation (intensity at frequency 2845 cm-1/intensity at frequency 2935 cm-1) on LNCaP AI CTL (top) and DECR1 KO (bottom) derived orthografts (left). Average Raman spectra of LNCaP AI CTL (grey) or DECR1 KO (magenta) orthografts (middle) and quantification of tumour lipid content using the 2845 cm−1-peak (right panel). AU = arbitrary unit. d Heatmap illustrating the steady-state levels of significantly regulated lipids in DECR1-deficient tumours when compared to CTL tumours (FC > 1.5, p < 0.05 using a two-tailed Student’s t-test). Values are expressed as z-score. a–c Data are presented as mean values +/− SD. a–c *p-value < 0.05 using a two-tailed Mann–Whitney U-test. BMP Bis(monoacylglycero)phosphate, Cer ceramide, PC phosphatidylcholine, PE phosphatidylethanolamine, PG phosphatidylglycerol, PI phosphatidylinositol, PS phosphatidylserine, TG triglyceride. Source data are provided as a Source data File.
